A nanoparticulate composition including particles comprising at least one active ingredient, wherein the particles have an effective average particle size is in the range of about 70 nm to about 220 nm measured by laser light scattering method, wherein at least 50% of said active agent particles have a particle size, by weight (volume based), of less than the effective average particle size; and (b) at least one surface stabilizer and/or at least one polymeric stabilizer, wherein the composition includes (aa) particles of at least one active ingredient selected from the group consisting of (Z)-2-cyano-3-cyclopropyl-3-hydroxy-N-(3-methyl-4-(trifluoromethyl)phenyl) prop-2-enamide, (Z)-2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]hept-2-en-6-ynamide, 2-cyano-3-cyclopropyl-N-(4-fluorophenyl)-3-hydroxyacrylamide, derivatives thereof, salts thereof and pro-drugs thereof, wherein the particles have an effective average particle size of less than about 2000 nm; and (bb) at least one surface stabilizer and/or at least one polymeric stabilizer.

A cancer drug for use in the treatment of cancer in which caffeic acid phenethyl ester (CAPE) is encapsulated in poly [lactic-co-glycolic acid] (PLGA) to increase its solubility in aqueous media is provided. Angiopep-2 is used as a specific ligand to increase biological activity. In an embodiment of the invention, PLGA is preferably in the form of nanoparticles, thereby ensuring better solubility.

The present disclosure relates to a compound of Formula (I)

##STR00001##

or a pharmaceutically acceptable salt thereof, which can be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid.

The subject invention provides materials and methods for intracellular deliver of molecules and/or therapeutic agents. The subject invention also provides methods for synthesizing polymeric systems and nanomaterials that enhance or assist the passage of molecules and/or therapeutic agents across biological membranes. The compound, polymer or nanoparticle of the subject invention comprises a modified guanidine moiety in a plurality of repeating units of a polymer or on the surface of a nanoparticle where the guanidine moiety comprises, for example, a carbamoyl or thiourea modification. The polymer or nanoparticle can be used in a cancer treatment formulation.

Formulated and/or co-formulated nanocarriers (e.g., LNPs and/or SLNPs) comprising ICD Prodrugs and methods of making the nanocarriers are disclosed herein. The ICD prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that induce immunogenic cell death (ICD). The ICD Prodrugs can be formulated and/or co-formulated into a nanocarrier to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.

In one aspect, compositions are described herein. A composition described herein comprises a nanoparticle, a therapeutic species, and a linker joining the nanoparticle to the therapeutic species. The linker joining the nanoparticle to the therapeutic species comprises a Diels-Alder cyclo-addition reaction product. Additionally, in some embodiments, the nanoparticle is a magnetic nanoparticle.

The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.

Methods disclosed herein provide for an environmentally-friendly approach that employ citric extracts from fruits as unique reducing and stabilizing agents for making a tellurium nanomaterial. A particular method of making a tellurium nanomaterial includes combining citrus fruit extract with a tellurium salt to form a mixture of citrus fruit extract and dissolved tellurium salt; and heating the mixture of citrus fruit extract and dissolved tellurium salt, thereby making the tellurium nanomaterial. The resulting nanoparticles exhibit enhanced and desirable biomedical properties toward treatment of both infectious diseases and cancer.

A method for formation of a vaccine comprising combining a cationic polymer adjuvant with an antigen to form first immunoparticles through charge interactions and producing a treatment formulation for the vaccine comprising the first immunoparticles.